2-[(3,4-dichlorophenyl)amino]-1,3-thiazole-4-carboxylic acid | 952182-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[(3,4-dichlorophenyl)amino]-1,3-thiazole-4-carboxylic acid
• 英文别名: 2-((3,4-dichlorophenyl)amino)thiazole-4-carboxylic acid；2-(3,4-Dichloroanilino)-1,3-thiazole-4-carboxylic acid
• CAS: 952182-44-4
• 化学式: C₁₀H₆Cl₂N₂O₂S
• 分子量: 289.142
• InChiKey: AWSZMFQURKXDAR-UHFFFAOYSA-N

物化性质

• 熔点：
  289～291℃
• 沸点：
  481.4±55.0 °C(Predicted)
• 密度：
  1.655±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  90.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(3,4-dichlorophenyl)amino]-1,3-thiazole-4-carboxylic acid 在 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 N-(3-(piperazin-1-yl)propyl) 2-((3,4-dichlorophenyl)amino)-thiazole-4-carboxamide
  参考文献：
  名称：

  在甲型流感病毒核蛋白三聚化过程中破坏保守的盐桥。

  摘要：

  流感感染中的抗病毒药物耐药性已成为对公共卫生的主要威胁。为了开发广谱的流感抑制剂来解决耐药性问题，我们之前确定了高度保守的核蛋白三聚体E339 ... R416盐桥为靶标，化合物1为通过EC50破坏盐桥的抑制剂甲型流感病毒= 2.7μM（A / WSN / 1933）。我们通过基于结构的方法进一步修饰了该化合物，并进行了抗病毒活性筛选，以鉴定化合物29和30的EC50值分别为110和120 nM，并且没有可测量的宿主细胞毒性。与临床使用的神经氨酸酶抑制剂相比，这两种化合物对耐药性A型流感病毒株和B型流感病毒显示出更好的活性，

  DOI：

  10.1021/acs.jmedchem.9b01244
• 作为产物：
  描述：

  1-(3,4-二氯苯基)-2-硫脲 在 sodium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 12.5h， 生成 2-[(3,4-dichlorophenyl)amino]-1,3-thiazole-4-carboxylic acid
  参考文献：
  名称：

  在甲型流感病毒核蛋白三聚化过程中破坏保守的盐桥。

  摘要：

  流感感染中的抗病毒药物耐药性已成为对公共卫生的主要威胁。为了开发广谱的流感抑制剂来解决耐药性问题，我们之前确定了高度保守的核蛋白三聚体E339 ... R416盐桥为靶标，化合物1为通过EC50破坏盐桥的抑制剂甲型流感病毒= 2.7μM（A / WSN / 1933）。我们通过基于结构的方法进一步修饰了该化合物，并进行了抗病毒活性筛选，以鉴定化合物29和30的EC50值分别为110和120 nM，并且没有可测量的宿主细胞毒性。与临床使用的神经氨酸酶抑制剂相比，这两种化合物对耐药性A型流感病毒株和B型流感病毒显示出更好的活性，

  DOI：

  10.1021/acs.jmedchem.9b01244

文献信息

• Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective Na_V1.7 Inhibitors
  作者：Erin F. DiMauro、Stephen Altmann、Loren M. Berry、Howard Bregman、Nagasree Chakka、Margaret Chu-Moyer、Elma Feric Bojic、Robert S. Foti、Robert Fremeau、Hua Gao、Hakan Gunaydin、Angel Guzman-Perez、Brian E. Hall、Hongbing Huang、Michael Jarosh、Thomas Kornecook、Josie Lee、Joseph Ligutti、Dong Liu、Bryan D. Moyer、Daniel Ortuno、Paul E. Rose、Laurie B. Schenkel、Kristin Taborn、Jean Wang、Yan Wang、Violeta Yu、Matthew M. Weiss

  DOI：10.1021/acs.jmedchem.6b00425

  日期：2016.9.8

  a parallel synthetic approach was applied to rapidly generate the derived acyl sulfonamides. A biaryl acyl sulfonamide hit from this library was elaborated, optimizing for potency and selectivity with attention to physicochemical properties. The resulting novel leads are potent, ligand and lipophilic efficient, and selective over hNaV1.5. Representative lead 36 demonstrates selectivity over other human

  大多数有效的和选择性的hNa V 1.7抑制剂具有常见的药理学特征，包括杂芳基磺酰胺头基和亲脂性芳族尾基。最近，已经出现了类似的芳香族尾基与酰基磺酰胺头基结合的报道，酰基磺酰胺赋予了相对于hNa V的选择性水平1.5与杂芳基磺酰胺相当。从满足亲脂性尾部中选定药理学要求的市售羧酸开始，采用平行合成方法快速生成衍生的酰基磺酰胺。精心制作了该文库中的联芳基酰基磺酰胺，优化了效价和选择性，并关注了理化性质。所得的新的铅是有效的，配体和亲脂性的，并且在hNa V 1.5上具有选择性。代表性的铅36证明了在鼠类中对其他人类Na V同工型的选择性和良好的药代动力学。与已知的杂芳基磺酰胺抑制剂相比，本文报道的联芳基酰基磺酰胺还可以提供ADME优势。
• [EN] THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS THIAZOLE UTILES EN TANT QU'INHIBITEURS DE PRMT5
  申请人：BAYER AG

  公开号：WO2019002074A1

  公开（公告）日：2019-01-03

  The present invention provides PRMT5 inhibiting compounds of general formula (I). A compound of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, L1 and L2 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of disorders, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

  本发明提供了通式(I)的PRMT5抑制化合物。通式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、L1和L2如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗过度增殖性疾病的药物组合物，作为唯一活性成分或与其他活性成分组合使用。
• SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS
  申请人：Polisetti Dharma Rao

  公开号：US20120029029A1

  公开（公告）日：2012-02-02

  The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable.

  本发明涉及取代噻唑-2-基胺衍生物及其药学上可接受的盐，其抑制11βHSD1并可能有助于治疗调节或抑制11βHSD1有益或需要降低细胞内糖皮质激素水平的疾病。本发明还涉及包含这些化合物的制药组合物以及在治疗调节或抑制11βHSD1有益或需要降低细胞内糖皮质激素水平的疾病、疾病或病况中使用这些化合物和组合物的用途。
• Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
  申请人：Polisetti Dharma Rao

  公开号：US08513430B2

  公开（公告）日：2013-08-20

  The present invention is directed to substituted thiazol-2-ylamine derivatives and pharmaceutically acceptable salts thereof that inhibit 11βHSD1 and that may be useful in the treatment of diseases in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation or inhibition of 11βHSD1 is beneficial or where a reduction in intracellular glucorticoid levels is desirable.

  本发明涉及取代噻唑-2-胺衍生物及其药学上可接受的盐，其抑制11βHSD1并可用于治疗调节或抑制11βHSD1有益或需要降低细胞内糖皮质激素水平的疾病。本发明还涉及包括这些化合物的制药组合物以及在治疗调节或抑制11βHSD1有益或需要降低细胞内糖皮质激素水平的这些疾病、疾病或病状中使用这些化合物和组合物的用途。
• Chemical screening of novel strigolactone agonists that specifically interact with DWARF14 protein
  作者：Rei Yasui、Yoshiya Seto、Shinsaku Ito、Kojiro Kawada、Kaori Itto-Nakama、Kiyoshi Mashiguchi、Shinjiro Yamaguchi

  DOI：10.1016/j.bmcl.2019.01.010

  日期：2019.4

  Strigolactones (SLs) are a class of plant hormones that regulate shoot branching as well as being known as root derived signals for parasitic and symbiotic interactions. The physical interaction between SLs and the DWARF14 (D14) receptor family can be examined by differential scanning fluorimetry (DSF) that monitors the changes in protein melting temperature (Tm). The Tm of D14 is lowered by bioactive SLs in DSF analysis. In this report, we screened the compounds that lower the Tm of Arabidopsis D14 (AtD14) as potential candidates for SL agonists using DSF analysis. Subsequent physiological analyzes revealed that 113D10 acts as a novel SL agonist in a D14 dependent manner. Intriguingly, 113D10 has a chemical structure different from natural SLs in that it does not possess an enol ether bond that connects to a methylbutenolide moiety. Moreover, 113D10 does not stimulate seed germination of root parasitic plants. Accordingly, 113D10 can be a useful tool for SL studies and agricultural applications.